Saturday, June 13, 2026

Novo Nordisk and Lilly Block Generics, Tighten Grip on $125B GLP-1 Market

Novo Nordisk and Eli Lilly secure court victories against generics, maintaining dominance in the GLP-1 treatment market amid rising demand.

AI Chatbots Dodge Politics: Google’s Gemini and Deepseek Models Avoid Key Questions

AI chatbots struggle with political questions due to censorship, impacting their response consistency and accuracy.

Stray Kids Break Their Own Records on Billboard—Fans Go Wild

Billboard announced on Tuesday that Stray Kids' mini album ATE and its title track, "Chk Chk Boom," had charted across 21 categories.

Tag: ALT-B4

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Alteogen and Biogen: A Game-Changing 200 Million USD License Deal for ALT-B4 Biopharmaceuticals

Alteogen partners with Biogen for exclusive licensing of subcutaneous biopharmaceuticals, potentially earning up to 549 million USD.

Alteogen Secures U.S. Patent for Keytruda Subcutaneous Injection: What This Means for ALT-B4 and Future Treatments

Alteogen secures a U.S. patent for a subcutaneous Keytruda formulation using ALT-B4, ensuring exclusivity until 2043 and potential $1B in sales.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.